Quality of Life in Lung Cancer Treatments
Author Information
Author(s): Kawahara Masaaki, Tada Harue, Tokoro Akihiro, Teramukai Satoshi, Origasa Hideki, Kubota Kaoru, Shinkai Tetsu, Fukushima Masanori, Furuse Kiyoyuki
Primary Institution: Otemae Hospital
Hypothesis
Does vinorelbine plus gemcitabine followed by docetaxel improve quality of life compared to paclitaxel plus carboplatin in patients with advanced non-small-cell lung cancer?
Conclusion
Patients treated with the vinorelbine plus gemcitabine regimen generally experienced better quality of life compared to those on the paclitaxel plus carboplatin regimen.
Supporting Evidence
- The VGD regimen showed a significant difference in the slope of the FACT-Taxane score.
- No significant differences were found in FACT-L and FACIT-Sp scores between the two groups.
- Patients in the VGD group maintained their quality of life scores over time.
Takeaway
This study looked at how different treatments for lung cancer affect patients' quality of life. One treatment seemed to help patients feel better than the other.
Methodology
Patients assessed their quality of life using specific questionnaires at baseline and at 6, 12, and 18 weeks after treatment.
Potential Biases
Patients with deteriorating quality of life were less likely to complete follow-up assessments, potentially biasing results.
Limitations
Sample size was smaller than expected and compliance with quality of life assessments was a challenge.
Participant Demographics
{"total":68,"male":56,"female":12,"median_age":65}
Statistical Information
P-Value
0.004
Statistical Significance
p = 0.004
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website